REVIEW article
Front. Immunol.
Sec. Inflammation
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1614589
This article is part of the Research TopicPrecision Medicine and Targeted Therapies in Gastrointestinal and Genitourinary Solid TumorsView all 9 articles
Research Progress of PYK2 in Digestive System Diseases
Provisionally accepted
Yiyao Duan1,2*Mingzhu Xie3Hui Wang1,2Sijing Chen1,2Jun Hu4
Chen Xu Jia1,2Hong Ping Jia1,2Ningyan Zhang1,2Ling Peng1,2Xiang Li5Hameed Ullah Khan1,2Die Hu6
Rong Qin1,2*- 1Yan'an Hospital Affiliated To Kunming Medical University, Kunming, Yunnan Province, China
- 2Key Laboratory of Tumor Immunological Prevention and Treatment of Yunnan Province, Kunming, Yunnan Province, China
- 3Kunming Maternity and Child Care Hospital, Kunming, Yunnan Province, China
- 4The First Hospital of Kunming, Kunming, Yunnan Province, China
- 5Kunming Medical University, Kunming, Yunnan Province, China
- 6Hunan University of Medicine, Huaihua, Hunan Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Belonging to the focal adhesion kinase (FAK) family, proline-rich tyrosine kinase 2 (PYK2) is a nonreceptor tyrosine kinase, has become a focal point in cancer research owing to its essential participation in the formation and dissemination of tumors. Studies have shown that this kinase controls various cellular activities, including: tumor cell adhesion, growth, multiplication, specialization, and detachment, making it a promising target for developing anticancer drugs. The goal of this review is to analyze the multifaceted role of PYK2 in gastrointestinal disease, focusing on its contribution to tumor progression, associated signaling pathways, and the therapeutic potential of PYK2 inhibitors in improving disease management and prognosis.Part of the FAK family, PYK2 is referred to as cellular adhesion kinase β (CAK-β), which is mainly distributed in the cytoplasm, and thus belongs to the Cytoplasmic tyrosine kinase [1][2][3]. This enzyme belongs to a unique group of protein kinases that target tyrosine residues on proteins for phosphorylation. Various cell types and tissues universally express PYK2, such as neural tissues, endothelial cells, brain cells, fibroblasts, platelets, and specific hematopoietic cells [4][5][6].
Keywords: Pyk2, Digestive System Diseases, targeted therapy, tumor progression, Signaling Pathways
Received: 19 Apr 2025; Accepted: 27 Jun 2025.
Copyright: © 2025 Duan, Xie, Wang, Chen, Hu, Xu Jia, Ping Jia, Zhang, Peng, Li, Khan, Hu and Qin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Yiyao Duan, Yan'an Hospital Affiliated To Kunming Medical University, Kunming, Yunnan Province, China
Rong Qin, Yan'an Hospital Affiliated To Kunming Medical University, Kunming, Yunnan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.